T2 Biosystems (TTOO) Reports Q4 Revenues Below Estimates; Provides Q1 & FY19 Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
T2 Biosystems Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
March 7, 2019 4:01 PM ESTSecured 14 New Instrument Contracts in the Fourth Quarter and 39 total New Instrument Contracts in 2018 that are expected to drive growth in Recurring Test Revenue
Confirms Guidance of a Doubling of Revenue in 2019; Provides Guidance of Securing 70 80 T2Dx Instruments Contracts in 2019
LEXINGTON, Mass., March 07, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today the operating highlights and financial results for the fourth quarter and year ended December 31, 2018. Â
Fourth Quarter... More
